Gilead Sciences Inc. said pre-market Tuesday that an HIV drug combination met primary endpoints in four late-stage clinical trials. The company said it plans to file for approval in the U.S. and Europe this year. Three of the studies looked at the combination's efficacy and safety relative to another HIV drug and patients switching from another HIV regimen. The fourth study compared virologically suppressed patients switching to the Gilead HIV combination to those on another regimen. Gilead's combination, the drugs bictegravir and emtricitabine/tenofovir alafenamide, are intended to treat HIV-1 infection in a single tablet regimen, and the latest results "could represent an important advance in triple-therapy treatment for a broad range of HIV patients," Gilead said. HIV drugs, along with Hepatitis C drugs, have become an important part of Gilead's revenue stream. Shares were up a scant 0.3% in pre-market trade. Shares have dropped 8.5% over the last three months, compared with a 2.2% rise in the S&P 500 .
Copyright © 2017 MarketWatch, Inc.
Continue Reading Below